Time to sell Bristol-Myers Squibb

There are better pipelines in the industry at a better price.

By Jim J. Jubak Dec 11, 2012 6:34PM
Image: Pills (Sean Justice/Corbis)On Friday, I announced in my post that I would be selling Bristol-Myers Squibb (BMY) out of my Jubak's Picks portfolio.

This year was never supposed to be a great year for Bristol-Meyers as generic competition ate further into sales of the company’s big drug, Plavix. In the third quarter the company reported a 43% year-to-year drop in U.S. sales due, largely to a 96% year-to-year drop in sales of Plavix.

In other words, 2012 was supposed to be a transition year. Sales were still likely to drop in 2013 from 2012 levels -- by about 5%, Standard & Poor’s projects -- but in 2013 the company was supposed to see a boost from drugs in its pipeline coming to market.

So the question for investors now is how much progress is that pipeline showing?

And there the picture has been mixed. A new anti-coagulant drug Eliquis, owned jointly with Pfizer (PFE), got a good review from European regulators that suggests a favorable outcome when the U.S. Food & Drug Administration rules on the drug again in March or before. The market for anti-coagulants is about $10 billion, so this could be a big drug although it will compete with other new drugs and warfarin, an old warhorse that continues to show surprising strength. (In June,the FDA refused to approve the drug and issued a complete response letter, which replaced
the agency’s non-approval letter under new regulations.)

But other news from the pipeline hasn’t been quite so good. In August, the company reported negative data on its hepatitis C drug BMS-986094 that has raised uncertainty about the strength of the company’s hepatitis pipeline. The launch of Bydureon for type 2 diabetes, a drug that Bristol-Myers acquired with its purchase of Amylin, has been relatively weak. Early indications are that it may be gaining market share mostly at the cost of an older Amylin diabetes drug Byetta. In July the company reported disappointing trial results for a cancer drug, Brivanib.

It’s always tough to judge the quality of a pipeline but I think there are better ones in the industry at a better price. Bristol-Myers current trades at a PEG (PE-to-growth rate) ratio of 2.22.

I added the stock to Jubak’s Picks at a price of $32.83 on August 3, 2012. The stock closed Friday at $32.56.

The shares carry a dividend yield of 4.27%. The next dividend of 35 cents a share is payable to shareholders of record on Jan. 4, 2013.

At the time of this writing, Jim Jubak didn't own shares of any companies mentioned in this post in personal portfolios. The mutual fund he manages, Jubak Global Equity Fund (JUBAX), may or may not own positions in any stock mentioned. The fund did not own shares of Bristol-Myers Squibb as of the end of September. For a full list of the stocks in the fund as of the end of the most recent quarter, see the fund's portfolio here. 

Tags: BMYJim JubakPFE
< Back to Top Stocks

MORE ON MSN MONEY

VIDEO ON MSN MONEY

User Picture
Write a comment...
0Comments

DATA PROVIDERS

Copyright © 2013 Microsoft. All rights reserved.

Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.

Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.

Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

127
127 rated 1		269
269 rated 2		463
463 rated 3		587
587 rated 4		658
658 rated 5		614
614 rated 6		644
644 rated 7		431
431 rated 8		262
262 rated 9		138
138 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
COPConocoPhillips10
NWSNews Ord Shs Class B10
YHOOYahoo! Inc10
TJXTJX Companies Inc9
AMXAmerica Movil ADR Rep 20 Ord Shs Series L9
More